Verve Therapeutics

Verve Therapeutics

生物技术研究

Boston,Massachusetts 32,805 位关注者

We are on a mission to protect the world from cardiovascular disease.

关于我们

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts.

网站
https://www.vervetx.com
所属行业
生物技术研究
规模
201-500 人
总部
Boston,Massachusetts
类型
私人持股
创立
2018

地点

  • 主要

    201 Brookline Ave

    Suite 601

    US,Massachusetts,Boston,02215

    获取路线

Verve Therapeutics员工

动态

相似主页

查看职位

融资

Verve Therapeutics 共 5 轮

上一轮

上市后股权

US$143,800,000.00

Crunchbase 上查看更多信息